Outpatient Department, Kyiv, Ukraine

LLC Treatment and Diagnostic Center ADONIS Plus

Crohn Disease

Diabetes Mellitus

Dyslipidemias

Triglycerides

Pemafibrate

Guselkumab

V565

Janssen (J&J Innovative Medicine)

Kowa

VHsquared

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

LLC Treatment and Diagnostic Center ADONIS Plus | Outpatient Department, Kyiv, Ukraine

Site insights

Work at this site?

Active trials

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Trial sponsors